مهارکننده رنین (Persian Wikipedia)

Analysis of information sources in references of the Wikipedia article "مهارکننده رنین" in Persian language version.

refsWebsite
Global rank Persian rank
2nd place
2nd place
4th place
5th place
6th place
9th place
3,608th place
3,828th place
low place
low place
low place
low place
18th place
50th place

ahajournals.org

circ.ahajournals.org

  • Gradman AH, Schmieder RE, Lins RL, Nussberger J, Chiang Y, Bedigian MP (March 2005). "Aliskiren, a novel orally effective renin inhibitor, provides dose-dependent antihypertensive efficacy and placebo-like tolerability in hypertensive patients". Circulation. 111 (8): 1012–8. doi:10.1161/01.CIR.0000156466.02908.ED. PMID 15723979.

archive.org

cvpharmacology.com

doi.org

  • Gradman AH, Schmieder RE, Lins RL, Nussberger J, Chiang Y, Bedigian MP (March 2005). "Aliskiren, a novel orally effective renin inhibitor, provides dose-dependent antihypertensive efficacy and placebo-like tolerability in hypertensive patients". Circulation. 111 (8): 1012–8. doi:10.1161/01.CIR.0000156466.02908.ED. PMID 15723979.
  • Nakano, Stephanie J.; Everitt, Melanie D. (2018). "Neurohormonal Axis and Natriuretic Peptides in Heart Failure". Heart Failure in the Child and Young Adult. Elsevier. pp. 75–86. doi:10.1016/b978-0-12-802393-8.00006-5. ISBN 978-0-12-802393-8.
  • Nussberger, Jürg (2005). "Renin Inhibitors". Hypertension. Elsevier. pp. 754–764. doi:10.1016/b978-0-7216-0258-5.50162-9. ISBN 978-0-7216-0258-5.
  • Lambers Heerspink, Hiddo J.; Fioretto, Paola; de Zeeuw, Dick (2014). "Pathogenesis, Pathophysiology, and Treatment of Diabetic Nephropathy". National Kidney Foundation Primer on Kidney Diseases. Elsevier. pp. 222–234. doi:10.1016/b978-1-4557-4617-0.00025-x. ISBN 978-1-4557-4617-0.
  • Lambers Heerspink, Hiddo J.; Fioretto, Paola; de Zeeuw, Dick (2014). "Pathogenesis, Pathophysiology, and Treatment of Diabetic Nephropathy". National Kidney Foundation Primer on Kidney Diseases. Elsevier. pp. 222–234. doi:10.1016/b978-1-4557-4617-0.00025-x. ISBN 978-1-4557-4617-0.
  • Jensen, C.; Herold, P.; Brunner, H. R. (2008). "Aliskiren: The first renin inhibitor for clinical treatment". Nature Reviews Drug Discovery. 7 (5): 399–410. doi:10.1038/nrd2550. PMID 18340340.
  • Gross, F.; Lazar, J.; Orth, H. (1972). "Inhibition of the renin–angiotensinogen reaction by pepstatin". Science. 175 (22): 656. Bibcode:1972Sci...175..656G. doi:10.1126/science.175.4022.656. PMID 4109853.

harvard.edu

ui.adsabs.harvard.edu

nih.gov

pubmed.ncbi.nlm.nih.gov

  • Gradman AH, Schmieder RE, Lins RL, Nussberger J, Chiang Y, Bedigian MP (March 2005). "Aliskiren, a novel orally effective renin inhibitor, provides dose-dependent antihypertensive efficacy and placebo-like tolerability in hypertensive patients". Circulation. 111 (8): 1012–8. doi:10.1161/01.CIR.0000156466.02908.ED. PMID 15723979.
  • Jensen, C.; Herold, P.; Brunner, H. R. (2008). "Aliskiren: The first renin inhibitor for clinical treatment". Nature Reviews Drug Discovery. 7 (5): 399–410. doi:10.1038/nrd2550. PMID 18340340.
  • Gross, F.; Lazar, J.; Orth, H. (1972). "Inhibition of the renin–angiotensinogen reaction by pepstatin". Science. 175 (22): 656. Bibcode:1972Sci...175..656G. doi:10.1126/science.175.4022.656. PMID 4109853.

teachmephysiology.com